Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Aribio Co. Ltd. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 actions are assigned to 4 distinct examiners and are located in 4 distinct art units, indicating a spread of technical subject matter within the life sciences. This lack of overlap means that each of the 4 pending office actions is being reviewed independently by different personnel in different administrative groups.
MOU, LIYUAN is the busiest examiner for the company, responsible for 1 pending office action. Because each of the 4 distinct examiners is only handling one case, the prosecution of the 4 pending office actions will likely follow 4 different timelines and sets of examiner preferences. The involvement of 4 distinct art units suggests that the company's pharmaceutical research covers several different specialized areas. Practitioners must tailor their strategies to the specific requirements of each of the 4 examiners and art units, as there is no central point of contact or shared examiner history to leverage across the portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 55.1% | +28.3% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991922 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | RAMOS LEWIS, JOSMALEN MILAGROS | 46d |
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 55d |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | BORALSKY, LUKE ALAN | 83d |
| 19003405 | COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1628 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | LEE, HOI YAN NMN | 1693 | §102§103Other | Non-Final OA | 55d | Pending | Dec 27, 2024 |
| 19003405 | COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | MOU, LIYUAN | 1628 | §103DP | Non-Final OA | — | Pending | Dec 27, 2024 |
| 18991922 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 46d | Pending | Dec 23, 2024 |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | 83d | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAribio Co. Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Hoi Yan Nmn Lee has the most, with 1 of Aribio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
